Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financial results and corporate highlights. “We have started 2024 with a focus on maintaining strong execution across our portfolio,” said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. “We continue to progress a robust RLY-2608 development program and expect to share additional data in the second half of the year. In parallel, we have continued to advance our pre-clinical pipeline and look forward to disclosing at least one new program this year, which is being designed to have first-in-class potential.” Recent Corporate Highlights RLY-2608 (ReDiscover study) RLY-2608 doublet: continued to enroll patients with PI3Ka-mutant, HR+, HER2- locally advanced or metastatic bre
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics to Host New Program and Platform Event on June 6, 2024 [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics to Host New Program and Platform Event on June 6, 2024GlobeNewswire
- Relay Therapeutics, Inc. (NASDAQ: RLAY) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $15.00 price target on the stock.MarketBeat
- VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug Discovery [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $24.00 price target on the stock.MarketBeat
RLAY
Earnings
- 5/2/24 - Beat
RLAY
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/29/24 - Form 4
- RLAY's page on the SEC website